are glp-1 agonists safe For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Current Insights, Advantages and Challenges

Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis

Patients should use one medication at a time under physician supervision

Revolutionizing GLP-1 delivery with sublingual administration Recently, a new sublingual modality for GLP-1 receptor agonists (and also for insulins) delivery has been developed by the Dutch company SUBLIN BV, established in 2018 as a spin-out of the healthcare branch of NanoServe BV

Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y

Author Contributions Stephano Cedirian, Michela Starace, Emanuel Raschi, Francesca Pampaloni, Monia Donati, Rossella Sgarzani, Luca Negosanti, Luca Rapparini and Michelangelo La Placa conceptualized and designed the study, conducted data collection and analysis, and wrote the initial draft of the manuscript